Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
J Thorac Oncol
; 15(9): 1449-1459, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-32389639
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
J Thorac Oncol
Year:
2020
Type:
Article